Literature DB >> 35983420

Clinical Overbasalization Revisited.

Mayer B Davidson1.   

Abstract

Entities:  

Year:  2022        PMID： 35983420      PMCID： PMC9331619          DOI： 10.2337/cd21-0132

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  12 in total

1.  When basal insulin is not enough: response to M Davidson.

Authors:  Guillermo E Umpierrez; Neil Skolnik; Terry Dex; Louise Traylor; Jason Chao; Charles Shaefer
Journal:  Diabetes Obes Metab       Date:  2019-12-05       Impact factor: 6.577

Review 2.  Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Maria Ida Maiorino; Paolo Chiodini; Giuseppe Bellastella; Annalisa Capuano; Katherine Esposito; Dario Giugliano
Journal:  Diabetes Care       Date:  2017-04       Impact factor: 19.112

3.  Practicable Measurement and Identification of Overbasalization.

Authors:  Kevin Cowart; Nicholas W Carris
Journal:  Clin Diabetes       Date:  2022-01

4.  The Clinical Definition of Overbasalization.

Authors:  Mayer B Davidson
Journal:  Clin Diabetes       Date:  2021-10

5.  Evaluation of a simple policy for pre- and post-prandial blood glucose self-monitoring in people with type 2 diabetes not on insulin.

Authors:  Katia Bonomo; Alessandro De Salve; Elisa Fiora; Elena Mularoni; Paola Massucco; Paolo Poy; Alice Pomero; Franco Cavalot; Giovanni Anfossi; Mariella Trovati
Journal:  Diabetes Res Clin Pract       Date:  2009-12-01       Impact factor: 5.602

6.  Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.

Authors:  K Cusi; G R Cunningham; J P Comstock
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

7.  Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.

Authors:  Helena W Rodbard; Stephen Gough; Wendy Lane; Lars Korsholm; Ditte-Marie Bretler; Yehuda Handelsman
Journal:  Endocr Pract       Date:  2014-04       Impact factor: 3.443

8.  When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control.

Authors:  Guillermo E Umpierrez; Neil Skolnik; Terry Dex; Louise Traylor; Jason Chao; Charles Shaefer
Journal:  Diabetes Obes Metab       Date:  2019-03-25       Impact factor: 6.577

9.  How much is too much? Outcomes in patients using high-dose insulin glargine.

Authors:  T Reid; L Gao; J Gill; A Stuhr; L Traylor; A Vlajnic; A Rhinehart
Journal:  Int J Clin Pract       Date:  2015-11-13       Impact factor: 2.503

10.  Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.

Authors:  Julio Rosenstock; Antonio Nino; Joseph Soffer; Lois Erskine; Andre Acusta; Jo Dole; Molly C Carr; Jason Mallory; Philip Home
Journal:  Diabetes Care       Date:  2020-07-21       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.